This grant serves as a catalyst for Resonate Bio’s mission to transform drug discovery using its pioneering hybrid AI-NMR technology. By capturing dynamic, movie-like ensembles of drug candidates bound to proteins, Resonate Bio enables structure-based drug design for disease-causing proteins previously considered undruggable due to their high flexibility.
“Securing the AWS DeepTech Pre-Seed Grant is a perfect beginning for us,” said Dr. Darryl McConnell, Managing Director of Resonate Bio. “It kick-starts our company and empowers us to expand the use cases for our AI-NMR platform. We deeply appreciate Austria Wirtschaftsservice’s support in helping innovative technologies reach real-world impact.”
Unlike traditional static imaging methods, Resonate Bio’s technology fuses advanced AI algorithms with high-resolution solution-phase NMR data to produce Resonate Structures – dynamic representations of drug-protein interactions. With AWS backing, the company will scale its operations, boost its research pipeline, and pursue strategic collaborations that unlock new therapeutic possibilities..
For more about Resonate Bio’s technology and mission, visit resonate.bio.